NEW YORK (GenomeWeb News) – Roche subsidiary Genentech will use Horizon Discovery's mutant-and-normal cell lines in its oncology drug research programs under a three year agreement, Horizon said today.
The agreement, which expands an ongoing relationship between the companies, will give Genentech access to Horizon's X-MAN cell-line library.
Earlier in 2009, Genentech licensed the rights to use Horizon's GENESIS gene engineering platform to develop genetically defined human cancer models for drug studies.
The relationship between the two companies "has yielded some exciting findings which are being translated into publications that will help others striving to develop targeted cancer agents," Paul Morrill, business development director at Horizon, said in a statement.
Horizon said that Genentech has agreed to pay up-front, milestone and renewal fees, but it did not provide specific details of the financial terms.